Abstracts Archive - Page 1280 of 2425 - ACR Meeting Abstracts

Abstract Number: 1117 • 2017 ACR/ARHP Annual Meeting
the Absolute Risk of Clinically Diagnosed Gout By Serum Uric Acid Levels – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden
Meliha C. Kapetanovic¹, Peter M Nilsson², Carl Turesson³, Martin Englund⁴, Nicola Dalbeth⁵, Lieke E.J.M. Scheepers⁶ and Lennart TH Jacobsson⁶, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Department of Clinical Sciences, Lund University, Skåne University Hospital Malmö, Sweden., Lund, Sweden, ³Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁴Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ⁵University of Auckland, Auckland, New Zealand, ⁶Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Hyperuricemia i.e. increased s-uric acid levels (s-UA), is established risk factor for clinical gout. Studies regarding the absolute and relative effect on population level…
Abstract Number: 1118 • 2017 ACR/ARHP Annual Meeting
Diabetes and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization
Douglas C.A. Taylor¹, An-Chen Fu¹ and Robert Morlock², ¹Ironwood Pharmaceuticals, Inc., Cambridge, MA, ²YourCareChoice, Ann Arbor, MI
Background/Purpose: Gout and type 2 diabetes mellitus (T2DM) are common in the United States (US), but little is known about potential associations of T2DM and…
Abstract Number: 1119 • 2017 ACR/ARHP Annual Meeting
Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US
Robert Morlock¹, Pierre Chevalier², An-Chen Fu³ and Douglas C.A. Taylor³, ¹YourCareChoice, Ann Arbor, MI, ²IMS Health, Zaventem, Belgium, ³Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Elevated sUA is associated with worsened…
Abstract Number: 1120 • 2017 ACR/ARHP Annual Meeting
Less Than Half of Patients Treated with High-Dose Allopurinol Reach Serum Uric Acid Target
Robert Morlock¹, Douglas C.A. Taylor² and Scott Baumgartner³, ¹YourCareChoice, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³drB Consulting, Spokane, WA
Background/Purpose: Although allopurinol is FDA approved for up to 800 mg per day and EMEA authorized for up to 900 mg per day, most patients…
Abstract Number: 1121 • 2017 ACR/ARHP Annual Meeting
Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?
Jean J. Lim^1,2, An-Chen Fu², Jami Giordano², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Urate-lowering therapy (ULT) is essential in chronic gout management. For decades, allopurinol has remained the most frequently prescribed ULT. Reaching a goal of serum…
Abstract Number: 1122 • 2017 ACR/ARHP Annual Meeting
Prevalence of Chronic Kidney Disease and Uncontrolled Serum Uric Acid Levels in US Adult Gout Population: Results from the National Health and Nutrition Examination Survey 2007–2012
Jean J. Lim^1,2, An-Chen Fu², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis, mainly caused by elevated serum uric acid (sUA) levels. The American College of Rheumatology guidelines…
Abstract Number: 1123 • 2017 ACR/ARHP Annual Meeting
Random Urinary Uric Acid/Creatinine Ratio Is Useful in the Estimation of 24-Hour Urine Uric Acid Excretion in Patients with Gout
Sang Tae Choi¹, Seong-Jin Moon² and Eun-Jin Kang³, ¹Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea, Republic of (South), ²Internal Medicine, Catholic Kwandong University College of Medicine, Incheon, Korea, Republic of (South), ³Internal Medicine, Busan Medical Center, Busan, Korea, Republic of (South)
Background/Purpose: Gout is a chronic inflammatory disease resulted from hyperuricemia. The measurement of 24-hour urinary uric acid excretion is frequently used to evaluate disease status…
Abstract Number: 1124 • 2017 ACR/ARHP Annual Meeting
Marked Variability of Circulating Urate Concentrations in Banked Samples Based on Sample Type and Assay
Evan M. Ryan¹, Michael J. Duryee², Susan K. Dover³, Elizabeth Schoenecker³, Risa Urbauer³, Flordeliza Faulkner³, Nicole Norotsky³, Harlan Sayles¹, Brian W Coburn⁴, Samuel Pirruccello¹, Geoffrey M. Thiele¹ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³U.S. Department of Veterans Affairs, Omaha, NE, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Circulating urate is an important biomarker, not only in the detection and management of gout, but also in assessing the risk of related comorbidity.…
Abstract Number: 1125 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Acute Gouty Arthritis in Patients Hospitalized with Acute Coronary Syndromes and Congestive Heart Failure
Gabriela Montes-Rivera¹, Carla F Gamarra-Hilburn², Lorena González-Sepúlveda³ and Luis M. Vilá⁴, ¹Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ³Puerto Rico Clinical and Translational Research Consortium, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁴Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Hyperuricemia and untreated gout appears to be independent prognostic markers for poor all-cause and coronary heart disease mortality in patients with recent acute myocardial…
Abstract Number: 1126 • 2017 ACR/ARHP Annual Meeting
High Osteoprotegerin:RANKL Ratios in Synovial Fluid Correlate with the Presence of Calcium Pyrophosphate Crystals
Ian Chang¹, Daisy Obiora², Ann Rosenthal³ and Charlene J. Williams⁴, ¹Medicine/Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ²Urology, Cooper Hospital, Camden, NJ, ³Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁴Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ
Background/Purpose: Calcium pyrophosphate deposition disease (CPDD) is a common cause of both acute and chronic arthritis in the elderly. It is estimated that twenty percent…
Abstract Number: 1127 • 2017 ACR/ARHP Annual Meeting
Replication of Genetic Association of Peroxisome Proliferator-Activated Receptor Gamma-1B with Gout in a New Zealand Polynesian Sample Set
Amara Shaukat¹, Tim Jansen², M. Janssen³, Leo .A.B. Joosten⁴, Timothy Radstake⁵, Philip Riches⁶, Anne-Kathrin Tausche⁷, Jennie Harre Hindmarsh⁸, Nicola Dalbeth⁹, Lisa K. Stamp¹⁰ and Tony R. Merriman¹¹, ¹Univ Otago, Dunedin, New Zealand, ²VieCuri Medical Center, Venlo, Netherlands, ³Rheumatology Dept, Rijnstate Hospital, Arnhem, Netherlands, ⁴Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶University of Edinburgh, Edinburgh, United Kingdom, ⁷Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ⁸Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, ⁹University of Auckland, Auckland, New Zealand, ¹⁰University of Otago, Christchurch, New Zealand, ¹¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Gout results from formation of monosodium urate (MSU) crystals in the presence of hyperuricemia. Genome wide association studies have provided significant insights into hyperuricemia,…
Abstract Number: 1128 • 2017 ACR/ARHP Annual Meeting
Effect of Urate-Lowering Treatment on the Risk of Urolithiasis in People with Gout
Wen-Ching Lan, Kuang-Hui Yu, Shue-Fen Luo, Chang-Fu Kuo and Tien-Ming Chan, Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Appropriate dose of urate-lowering therapy (ULT) is needed for gout patients to dissolve existing urate crystals to prevent acute gout attacks and reduce the…
Abstract Number: 1129 • 2017 ACR/ARHP Annual Meeting
Impact of Diuretics on Urate Lowering Therapy in Patients with Gout: Analysis of an Inception Cohort
Laura Ranieri¹, Carolina Contero², Pedro Zapater^3,4 and Mariano Andrés^1,5, ¹Sección de Reumatología, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, ²Departamento de Medicina Clínica, UNIVERSIDAD MIGUEL HERNÁNDEZ, Alicante, Spain, ³Sección de Farmacología Clínica, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, ⁴Departamento de Farmacología, Pediatría y Química Orgánica, UNIVERSIDAD MIGUEL HERNÁNDEZ, Alicante, Spain, ⁵Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain
Background/Purpose: Diuretics have been associated with impaired response to allopurinol and refractoriness in gout, but whether this stills after new urate-lowering treatments (ULT) and treat-to-target…
Abstract Number: 1130 • 2017 ACR/ARHP Annual Meeting
Can Alcohol Intake in Moderation Lower the Risk of Myocardial Infarction and Mortality Even Among Gout Patients?
Sarah Keller¹, Sharan K. Rai², Na Lu¹, April Jorge³, Yuqing Zhang⁴ and Hyon K. Choi², ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Alcohol is a well-established risk factor for gout. However, more than 60 prospective studies have also shown that moderate alcohol intake is associated with…
Abstract Number: 1131 • 2017 ACR/ARHP Annual Meeting
The Dietary Approaches to Stop Hypertension (DASH) and Mediterranean Diets and Risk of Gout in Women: 28-Year Follow-up of a Prospective Cohort
Sarah Keller¹, Sharan K. Rai², Leo Lu³, Yuqing Zhang⁴ and Hyon K. Choi², ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: There is increasing recognition of a gout epidemic, exacerbated by an unhealthy diet and a sedentary lifestyle. Indeed, our recent study among men confirmed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].